Analysts Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) PT at $24.83

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) have been given an average rating of "Buy" by the eight ratings firms that are covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $24.83.

Several equities research analysts recently issued reports on KALV shares. Citizens Jmp raised KalVista Pharmaceuticals to a "strong-buy" rating in a research note on Friday, January 31st. Jones Trading reissued a "buy" rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. JMP Securities started coverage on KalVista Pharmaceuticals in a research note on Friday, January 31st. They issued an "outperform" rating and a $19.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th.

Insiders Place Their Bets

In related news, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the stock in a transaction dated Wednesday, April 9th. The shares were acquired at an average price of $9.42 per share, with a total value of $235,500.00. Following the acquisition, the insider now owns 5,303,985 shares in the company, valued at approximately $49,963,538.70. The trade was a 0.47% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 5,104 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $50,121.28. Following the transaction, the chief executive officer now directly owns 278,855 shares in the company, valued at approximately $2,738,356.10. This represents a 1.80% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 17,292 shares of company stock valued at $184,625 in the last three months. Insiders own 10.50% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Suvretta Capital Management LLC increased its holdings in shares of KalVista Pharmaceuticals by 16.6% during the 4th quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company's stock valued at $41,613,000 after acquiring an additional 701,007 shares during the last quarter. Tang Capital Management LLC boosted its stake in KalVista Pharmaceuticals by 13.2% during the 4th quarter. Tang Capital Management LLC now owns 4,893,847 shares of the specialty pharmaceutical company's stock valued at $41,451,000 after purchasing an additional 572,300 shares during the period. Frazier Life Sciences Management L.P. boosted its stake in KalVista Pharmaceuticals by 32.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock valued at $41,400,000 after purchasing an additional 1,200,000 shares during the period. Vestal Point Capital LP boosted its stake in KalVista Pharmaceuticals by 19.3% during the 4th quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after purchasing an additional 770,000 shares during the period. Finally, Vanguard Group Inc. boosted its stake in KalVista Pharmaceuticals by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company's stock valued at $26,526,000 after purchasing an additional 43,355 shares during the period.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock traded up $0.22 during mid-day trading on Friday, hitting $11.56. The company's stock had a trading volume of 55,372 shares, compared to its average volume of 418,071. The firm's 50 day moving average is $12.03 and its 200 day moving average is $10.43. The company has a market cap of $574.57 million, a PE ratio of -3.17 and a beta of 0.05. KalVista Pharmaceuticals has a 52-week low of $7.30 and a 52-week high of $15.50.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).